Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Colorectal Cancer Clinical Trials in Tennessee | 449 Studies

Clinical Trials Colorectal CancerTennessee

Colorectal Cancer Clinical Trials in Tennessee

Find 449 clinical trials for colorectal cancer near Tennessee. Connect with research centers in your area.

All Colorectal Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 241-260 of 449 trials

RecruitingTesting the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur TrialThis phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced…NCT05673148·Kingman, Arizona and 186 others

Colorectal Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedStudy of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in…NCT04348916·Duarte, California and 10 others

Active not recruitingA Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursThe purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours.NCT06305247·Los Angeles, California and 10 others

TerminatedStudy of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal CancerStudy BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study.NCT01309126·Florence, Alabama and 52 others

Active not recruitingA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorThe primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer…NCT04008797·Little Rock, Arkansas and 105 others

Active not recruitingStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).NCT04956640·Birmingham, Alabama and 48 others

CompletedBRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)This was a four part, phase I/II study aimed to evaluate the safety, tolerability and efficacy of combination of an anti-EGFR antibody panitumumab (P) either with a BRAF inhibitor…NCT01750918·Scottsdale, Arizona and 19 others

CompletedS0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal CancerRATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…NCT00686166·Mobile, Alabama and 129 others

CompletedFOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal CancerThis randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line…NCT01418222·San Francisco, California and 22 others

CompletedPAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation StudyThis is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in…NCT00911170·Muscle Shoals, Alabama and 153 others

CompletedStudy of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerThis is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either…NCT02928224·Phoenix, Arizona and 417 others

Active not recruitingA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsTo evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability…NCT05907304·San Francisco, California and 28 others

RecruitingStudy of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsThis study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.NCT06040541·Sacramento, California and 16 others

RecruitingA First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsA first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced…NCT07629960·Sarasota, Florida and 15 others

CompletedA Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsThis is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of…NCT04853017·Duarte, California and 9 others

TerminatedSurufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsThis open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.NCT04579757·Tucson, Arizona and 17 others

RecruitingSolid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingObjective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect…NCT04981119·Gilbert, Arizona and 15 others

Active not recruitingDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerThis randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating…NCT02888743·Phoenix, Arizona and 41 others

CompletedPhase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal CancerTo determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.NCT00707889·Chapel Hill, North Carolina and 45 others

CompletedEffect of Panitumumab on the Pharmacokinetics of IrinotecanThe primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.NCT00563316·Billings, Montana and 11 others

PreviousPage 13 of 23Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Melanoma Leukemia Lymphoma